Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB raised its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 32.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,000 shares of the company's stock after purchasing an additional 30,000 shares during the period. E. Ohman J or Asset Management AB owned 0.15% of Scholar Rock worth $977,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. American International Group Inc. increased its stake in Scholar Rock by 3.0% in the first quarter. American International Group Inc. now owns 28,407 shares of the company's stock worth $505,000 after purchasing an additional 834 shares during the period. Jennison Associates LLC grew its stake in Scholar Rock by 1.0% in the 1st quarter. Jennison Associates LLC now owns 138,458 shares of the company's stock worth $2,459,000 after acquiring an additional 1,409 shares in the last quarter. Rice Hall James & Associates LLC increased its position in shares of Scholar Rock by 3.6% during the second quarter. Rice Hall James & Associates LLC now owns 46,000 shares of the company's stock worth $383,000 after acquiring an additional 1,594 shares during the period. ProShare Advisors LLC raised its stake in shares of Scholar Rock by 11.7% during the first quarter. ProShare Advisors LLC now owns 15,412 shares of the company's stock valued at $274,000 after acquiring an additional 1,620 shares in the last quarter. Finally, ClariVest Asset Management LLC boosted its holdings in shares of Scholar Rock by 3.0% in the second quarter. ClariVest Asset Management LLC now owns 59,640 shares of the company's stock valued at $497,000 after purchasing an additional 1,718 shares during the period. 91.08% of the stock is owned by institutional investors.

Insider Transactions at Scholar Rock

In related news, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $26.56, for a total value of $5,477,734.40. Following the completion of the transaction, the chief financial officer now directly owns 161,088 shares of the company's stock, valued at $4,278,497.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Scholar Rock news, Director Srinivas Akkaraju sold 1,175,713 shares of Scholar Rock stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the completion of the sale, the director now owns 5,612,896 shares of the company's stock, valued at approximately $164,177,208. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $26.56, for a total value of $5,477,734.40. Following the completion of the transaction, the chief financial officer now directly owns 161,088 shares in the company, valued at $4,278,497.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,415,340 shares of company stock worth $40,666,088. Insiders own 26.20% of the company's stock.

Scholar Rock Stock Up 3.1 %

Scholar Rock stock traded up $0.90 during trading hours on Friday, reaching $29.91. The stock had a trading volume of 1,064,652 shares, compared to its average volume of 1,148,666. The company has a market cap of $2.39 billion, a price-to-earnings ratio of -14.31 and a beta of 0.82. The business's 50 day moving average price is $14.77 and its 200-day moving average price is $12.07. Scholar Rock Holding Co. has a 52 week low of $6.76 and a 52 week high of $35.38. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.04 and a quick ratio of 6.04.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.01. During the same quarter in the prior year, the business posted ($0.47) EPS. Sell-side analysts anticipate that Scholar Rock Holding Co. will post -2.37 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on SRRK shares. JPMorgan Chase & Co. raised their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an "overweight" rating in a report on Monday, October 14th. Piper Sandler raised their price target on Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a research note on Tuesday, October 15th. HC Wainwright upped their price objective on shares of Scholar Rock from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Wedbush raised their target price on shares of Scholar Rock from $27.00 to $37.00 and gave the company an "outperform" rating in a research report on Monday, October 7th. Finally, BMO Capital Markets upped their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an "outperform" rating in a research report on Friday, October 11th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $33.29.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.